J. Rotow

发表

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation

C. Blakely, D. Jablons, T. Bivona, 2019, Clinical lung cancer.

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer

E. Collisson, F. Kaye, I. Yeh, 2018 .

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer

Franziska Haderk, Siraj M. Ali, D. Tan, 2020, bioRxiv.

Title: Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer

E. Collisson, F. Kaye, Wei Wu, 2019 .

Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis.

P. Jänne, D. Barbie, K. Kehl, 2020, JCO precision oncology.

The role of APOBEC3B in lung tumour evolution and targeted therapy resistance

E. V. Van Allen, R. Harris, W. Brown, 2022, bioRxiv.

Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing

Erin L. Schenk, Sourav Bandyopadhyay, N. Neff, 2020, Cell.

A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

Sourav Bandyopadhyay, J. Roth, J. Riess, 2021, bioRxiv.

Understanding and targeting resistance mechanisms in NSCLC

T. Bivona, J. Rotow, 2017, Nature Reviews Cancer.

Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer

Jeffrey W. Clark, B. Chabner, J. Gainor, 2013, Pharmacological Reviews.

Aurora kinase A drives the evolution of resistance to third generation EGFR inhibitors in lung cancer

Sourav Bandyopadhyay, V. Wang, F. McCormick, 2018, Nature Medicine.

Heterogeneity and targeted therapy-induced adaptations in lung cancer revealed by longitudinal single-cell RNA sequencing

Erin L. Schenk, N. Neff, J. Weissman, 2019, bioRxiv.

Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

E. Collisson, F. Kaye, I. Yeh, 2019, Clinical Cancer Research.

Co-occurring genetic alterations in the RAS pathway promote resistance to MET inhibitor treatment in non-small cell lung cancer with a MET exon 14 skipping mutation

E. Collisson, F. Kaye, I. Yeh, 2018, bioRxiv.

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

Maximilian Diehn, Charles Swanton, Wei Wu, 2017, Nature Genetics.

RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis.

D. Slamon, C. Ginther, A. Koegel, 2010, Lung cancer.

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.

J. Riess, R. Doebele, R. Nichols, 2018, Cancer research.

Evolution and clinical impact of genetic epistasis within EGFR-mutant lung cancers

V. Wang, C. Swanton, J. Chabon, 2017, bioRxiv.

Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance

E. V. Van Allen, W. Brown, A. Rowan, 2020, bioRxiv.

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

S. Digumarthy, J. Neal, H. Wakelee, 2023, JTO clinical and research reports.

Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer

J. Schlom, R. Madan, J. Gulley, 2010, Clinical and translational science.

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience

J. Neal, H. Wakelee, L. Sequist, 2022, JTO clinical and research reports.

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma

P. Munster, A. Daud, A. Algazi, 2019, Pigment cell & melanoma research.

Aurora kinase A drives the evolution of resistance to third generation EGFR inhibitors in lung cancer

Sourav Bandyopadhyay, V. Wang, F. McCormick, 2018, Nature Medicine.

FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions

A. Drilon, M. Scheffler, J. Goldman, 2021 .

Targeted Therapy for Non-Small Cell Lung Cancer: First Line and Beyond.

E. Brea, J. Rotow, 2023, Hematology/oncology clinics of North America.

Abstract CT184: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1/2 SYMPHONY study

K. Goto, D. Spigel, K. Reckamp, 2022, Cancer Research.

What's Old Is New Again: Revisiting Up-Front Chemotherapy in EGFR-Mutated Non-Small-Cell Lung Cancer.

P. Jänne, J. Rotow, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.

J. Neal, H. Wakelee, J. Riess, 2020, Journal of Clinical Oncology.

P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results

J. Riess, R. Doebele, K. Jones, 2021, Journal of Thoracic Oncology.

Evolution and clinical impact of genomic alterations detectable in circulating tumor DNA of 1150 advanced EGFR-mutant (mt) lung cancer patients.

V. Wang, J. Riess, R. Doebele, 2017 .

A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

D. Camidge, K. Goto, S. Gadgeel, 2022, Journal of Clinical Oncology.

Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).

C. Paweletz, P. Jänne, D. Costa, 2020 .

22P EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results

P. Jänne, N. Gabrail, Y. Wu, 2022, Annals of Oncology.

FP01.05 The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation +/- Surgery for Stage III EGFR-Mutant NSCLC

P. Jänne, R. Mak, M. Mino‐Kenudson, 2021 .

Anaphylaxis and systemic mastocytosis controlled with KIT inhibitors in a patient with metastatic lung adenocarcinoma.

G. Oxnard, M. Castells, J. Rotow, 2023, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.